Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 9 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 9 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1

6(66.7%)

Phase 2

3(33.3%)

9Total

Phase 1(6)

Phase 2(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT02408055Phase 1Completed

ADME Study in Healthy Male Subjects With TA-8995

Role: lead

NCT02124954Phase 1Completed

A Preliminary Drug Drug Interaction Study With TA-8995

Role: lead

NCT02523391Phase 1Completed

Bioequivalence Study of Capsule and Tablet Formulations of TA-8995

Role: lead

NCT02233699Phase 2Completed

A Study to Assess the Efficacy of XEN-D0501 in Reducing the Cough Frequency in Patients With Chronic Idiopathic Cough

Role: lead

NCT02233686Phase 2Completed

A Study to Assess the Efficacy of XEN-D0501 in Reducing the Cough Frequency in Patients With COPD

Role: lead

NCT02390258Phase 1Completed

Fed-Fasted, Single and Multiple Ascending Dose Trial of XEN-D0103

Role: lead

NCT02241759Phase 1Completed

Study of the Electrocardiographic Effects of TA-8995

Role: lead

NCT02241772Phase 1Completed

A Study on the Effects of TA-8995 on Lp(a) in Subjects With Elevated Lp(a)

Role: lead

NCT01970215Phase 2Completed

TA-8995: Its Use in Patients With Mild Dyslipidaemia (TULIP)

Role: lead

All 9 trials loaded